← Back to Search

Remote Ischemic Preconditioning for Contrast-Induced Acute Kidney Injury (RIP-CI-AKI Trial)

N/A

Recruiting

Research Sponsored by Salehin, Salman

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients presenting with a renal clearance in the range of less than 60 ml/min/1.73 m2 but not declared ESRD

Be older than 18 years old

Must not have

Impossibility to perform RIPC, caused by pathology in both arms (e.g. dystrophy, recent trauma, chronic wounds)

Percutaneous coiling/embolization procedures of the kidney

Timeline

Screening 3 weeks

Treatment Varies

Follow Up patient's serum creatinine would be measured 48-72 hours after coronary angiogram, and re-measured 6 weeks after coronary angiogram.

Awards & highlights

No Placebo-Only Group

Summary

This trial will test the feasibility, safety, and effectiveness of remote ischemic preconditioning (RIPC) as a means of reducing the incidence of contrast-induced nephropathy (CI-AKI) in patients undergoing coronary angiography (CA) or other diagnostic contrast studies.

Who is the study for?

This trial is for adults with kidney function less than normal (renal clearance <60 ml/min/1.73 m2) who are about to undergo a radiological procedure using contrast, like a coronary angiogram. It's not for those under 18, without consent, very low blood pressure, certain heart conditions, on dialysis or with recent contrast exposure.

What is being tested?

The study tests Remote Ischemic Preconditioning (RIPC), a non-invasive technique that might prevent kidney damage from contrast used in imaging procedures like coronary angiograms. The goal is to see if RIPC can reduce the risk of acute kidney injury when added to standard care.

What are the potential side effects?

RIPC is considered safe and has no reported adverse effects. It's a simple method where blood flow is temporarily stopped and then restored to an arm or leg which may help protect kidneys from damage during contrast imaging.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney function is low but I don't have end-stage renal disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I cannot have RIPC due to conditions in both arms.

Select...

I have had a procedure to block blood flow to my kidney.

Select...

I need medication through an IV for a severe heart condition.

Select...

I need an urgent heart artery exam due to a severe heart attack.

Select...

I am under 18 years old.

Select...

I am currently on dialysis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ patient's serum creatinine would be measured 48-72 hours after coronary angiogram, and re-measured 6 weeks after coronary angiogram.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~patient's serum creatinine would be measured 48-72 hours after coronary angiogram, and re-measured 6 weeks after coronary angiogram.

This trial's timeline: 3 weeks for screening, Varies for treatment, and patient's serum creatinine would be measured 48-72 hours after coronary angiogram, and re-measured 6 weeks after coronary angiogram. for reporting.